Loading...
•
Dec 31, 2021
Matinas BioPharma Q4 2021 Earnings Report
Matinas BioPharma reported financial results for the fourth quarter and full year ended December 31, 2021.
Key Takeaways
Matinas BioPharma reported a net loss attributable to common shareholders of $6.7 million, or a net loss of $0.03 per share for the fourth quarter of 2021. The company's cash, cash equivalents and marketable securities were approximately $49.6 million at the end of the year, which is expected to fund planned operations through 2023.
Fifteen patients enrolled to date in Cohort 4 of EnACT with topline interim data expected in Q3 2022.
Potential pathway to NDA submission for MAT2203 with confirmatory data to come from Cohort 5 of EnACT Trial.
Second in vivo study of Oral LNC-remdesivir to commence in March 2022.
Moving aggressively into Nucleic Acids with Internal Discovery Programs Initiated with mRNA, DNA and Antisense Oligonucleotides (ASOs).
Matinas BioPharma
Matinas BioPharma
Forward Guidance
Based on current projections, the Company believes that cash on hand is sufficient to fund planned operations through 2023.